Novavax’s alliance with Sanofi came at an opportune time for the beleaguered vaccine developer. Its protein-based Covid-19 vaccine never reached the revenue highs achieved by the messenger RNA ...

Novavax, Inc.'s valuation remains too high given its reliance on one-off revenues, uncertain royalties, and a complex Sanofi partnership. The company's Q1 2025 earnings were boosted by non-recurring ...

Novavax, Inc. (NASDAQ: NVAX) shares are trading higher Tuesday after the company announced it entered into a license agreement with Pfizer, Inc. (NYSE: PFE) for use of its Matrix-M adjuvant. Under the ...

Novavax, Inc. receives a Hold rating, reflecting improved prospects after its Sanofi partnership and upgraded 2025 revenue guidance to $1–1.05 billion. The SNY deal provides upfront payments, ...